MAP2K7 and non-small cell lung carcinoma: The efficacy of dual BRAF and meiotic chromosome‐axis‐associated kinase (MEK) inhibitors has been evaluated in previously treated and untreated patients with BRAF V600E‐mutant metastatic NSCLC, in whom it achieved overall response rates of 63%–64% and complete response rates of 4%–6%.3, 4